High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment

Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virology Vol. 83; no. 21; p. 11407
Main Authors: Gonzalez, Veronica D, Falconer, Karolin, Blom, Kim G, Reichard, Olle, Mørn, Birgitte, Laursen, Alex Lund, Weis, Nina, Alaeus, Annette, Sandberg, Johan K
Format: Journal Article
Language:English
Published: United States 01.11.2009
Subjects:
ADP-ribosyl Cyclase 1 - immunology
Adult
Antiretroviral Therapy, Highly Active
Antiviral Agents - therapeutic use
Disease Progression
Female
Hepacivirus - immunology
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatitis C, Chronic - virology
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV-1 - immunology
Humans
Interferon-alpha - immunology
Interferon-alpha - therapeutic use
Lymphocyte Activation - immunology
Male
Middle Aged
Ribavirin - therapeutic use
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - virology
T-Lymphocytes - immunology
T-Lymphocytes - virology
Viral Load
Young Adult
ISSN:1098-5514, 1098-5514
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1098-5514
1098-5514
DOI:10.1128/JVI.01211-09